Inside the research

ICU Medical, Inc.

ICUI Research profile · latest available data

Price overview

$164.95

▼ -1.07 (-0.6%)

52w hi$187.26
52w lo$114.13
Vol201.70K
As of25 Sep 2026

The Verdict

Hold

Our score +0.03

Short+0.14
Medium+0.10
Long-0.35

computed 2026-09-27

Key fundamentals

ICU Medical, Inc.

Healthcare · Medical Instruments & Supplies

Market cap$4.12B
Enterprise value$5.11B
Trailing P/E138.61x
Forward P/E17.10x
EV / EBITDA15.67x
P / S (ttm)1.91x
Profit margin1.4%
Return on equity1.4%
Revenue growth+0.5%
Earnings growth-46.9%
Debt / equity59.82

Layer Breakdown

LayerRawContribution
Fundamental-0.02
Sector+0.08
Technical+0.08
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-09-27

Business overview

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.

United States · www.icumed.com

Risk Metrics

Beta vs SPX1.03
Corr SPX0.44
Annual vol38.1%
Annual ret+3.8%
Sharpe0.10
Max DD-41.2%

Window: 504 trading days (504 obs)

Material Events

DateEvent8-K
2026-08-06Earnings Release, Exhibitsread
2026-05-18Bylaws Amendment, Shareholder Vote…read
2026-05-07Earnings Release, Exhibitsread
2026-02-20Officer / Director Change, Exhibitsread
2026-02-19Earnings Release, Exhibitsread
2025-11-06Earnings Release, Exhibitsread
2025-08-07Earnings Release, Exhibitsread
2025-05-14Officer / Director Change, Shareholder Vote…read
2025-05-08Earnings Release, Exhibitsread
2025-02-27Earnings Release, Exhibitsread
2024-11-12Earnings Release, Exhibitsread
2024-10-02Officer / Director Changeread

Insider Trades

DateInsiderRoleActionSharesValue
2026-08-13Woolson DanielVP, GM-Infusion CapitalSell5.42K$982.26K
2026-08-12Sousa BenChief Information OfficerSell2.25K$401.21K
2026-08-11Voigtlander Christian B.Chief Operating OfficerSell8.93K$1.63M
2026-08-11FINNEY ELISHA WSell378$68.98K
2026-05-22Woolson DanielPresidentSell2.12K$280.68K
2026-05-14Sanzone Virginia RuthVP, General CounselSell2.45K$303.62K
2026-05-13KENNEDY KOLLEEN TOption exercise1.25K—
2026-05-13Hernandez LaurieOption exercise1.25K—
2026-05-13FINNEY ELISHA WOption exercise1.25K—
2026-05-13Abbey DonaldOption exercise1.25K—

Flow & Concentration

Insider 180d net-$3.67M
Insider buys / sells0 / 6
Insider biasSellers
13F holders0
Top-5 share0.0%
HHI0 (—)

SEC Filings

DateFormDoc
2026-08-134view
2026-08-124view
2026-08-114view
2026-08-114view
2026-08-0610-Qview
2026-08-068-Kview
2026-05-224view
2026-05-188-Kview
2026-05-154view
2026-05-134view
2026-05-134view
2026-05-134view
2026-05-134view
2026-05-134view
2026-05-134view

The Long Run

FY 2009–2025 · 17 years

LineLatestCAGRTrend
Revenue$2.26B+16.8%
Gross profit$822.04M+14.8%
Operating income$22.82M-3.6%
Net income$732.00K-30.7%
Cash from ops$179.85M+9.1%

Indices

S&P SmallCap 600

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$166.43$166.67$163.95$164.95201.70K
Sep 24$163.12$167.67$163.08$166.02380.10K
Sep 23$160.26$166.46$159.29$163.32408.30K
Sep 22$157.64$163.57$156.01$160.98276.00K
Sep 21$154.25$156.80$152.49$155.22223.40K

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →